Kineta Provides Update On Its Ongoing Phase 1/2 VISTA-101 Clinical Trial And Corporate Activities; Received $500,000 Investment From An Existing Investor

5/15/24 4:21:11 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $KA alert in real time by email

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts

Favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of CRS-associated cytokines observed at any dose level

Cleared fifth of six monotherapy cohorts and second of four combination cohorts

Kineta is actively exploring strategic alternatives to maximize value for all stakeholders

Received $500,000 investment from an existing investor

Get the next $KA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$KA

Date	Price Target	Rating	Analyst

More analyst ratings

$KA
Press Releases

Fastest customizable press release news feed in the world

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors
Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial. The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). The company will present additional scientific data in 2024 at an upcoming scientific meeting. SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC:KANT) ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has completed the enrollment of new patients into the monotherapy arm of the VI
10/8/24 9:00:00 AM ET
$KA
Biotechnology: Pharmaceutical Preparations
Health Care
Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC:KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its abstract on the KVA12123 clinical program has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting to be held November 6-10, 2024, in Houston, Texas and virtually. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, has announced that on November 8, 2024 Jason Henry M.D., Associate Director, Drug Development at Sarah Cannon Research Institute, Denver Colorado will be presenting the poster wi
10/4/24 9:05:00 AM ET
$KA
Biotechnology: Pharmaceutical Preparations
Health Care
Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1
TuHURA has extended their exclusivity and right of first offer pursuant to the terms of the agreement. Kineta and TuHURA are collaborating on the ongoing Phase 1/Phase 2 clinical trial in patients with advance solid tumor cancer SEATTLE, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (OTC:KANT) ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that TuHURA Biosciences Inc (TuHURA) is exercising its right to extend their exclusivity and right of first offer agreement (the "Agreement") for Kineta's VISTA blocking antibody KVA12123. Under the terms of the A
10/2/24 4:05:00 PM ET
$KA
Biotechnology: Pharmaceutical Preparations
Health Care

$KA
Market Insights

Live Market Insights

Kineta shares are trading higher after the company announced that it entered into an exclusivity and right of first offer agreement with TuHURA Biosciences to grant the immune-oncology company exclusive rights to acquire its Anti-VISTA antibody.
7/8/24 7:34:52 AM ET
$KA
Biotechnology: Pharmaceutical Preparations
Health Care
TuHURA Biosciences And Kintara Therapeutics Announce Agreement For Potential Acquisition Of Kineta's Anti-VISTA Antibody
KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel the tumor microenvironment (TME) to overcome acquired resistance to immunotherapies KVA12123 is currently in a Phase 1/Phase 2 clinical study as a monotherapy and in combination with Merck's anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors To date, KVA12123 has demonstrated a favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of Cytokine Release Syndrome (CRS) associated toxicities at doses examined Concurrent $5 million investment from existing TuHURA shareholder preserves
7/8/24 6:35:50 AM ET
$KA
$KTRA
Biotechnology: Pharmaceutical Preparations
Health Care
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 68.1% to $1.0 during Thursday's after-market session. The market value of their outstanding shares is at $13.3 million. Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 15.67% to $0.32. The market value of their outstanding shares is at $17.5 million. Talphera (NASDAQ:TLPH) shares rose 12.64% to $0.92. The market value of their outstanding shares is at $15.6 million. Helius Medical Tech (NASDAQ:HSDT) shares moved upwards by 10.11% to $1.06. The market value of their outstanding shares is at $3.1 million. Clover Health Investments (NASDAQ:CLOV) stock rose 9.72% to $1.13. The company's market cap stands at $561.0 mil
6/20/24 4:31:11 PM ET
$ALZN
$CLNN
$CLOV
$ENSC
Biotechnology: Pharmaceutical Preparations
Health Care
Medical Specialities
Biotechnology: Electromedical & Electrotherapeutic Apparatus

Kineta Provides Update On Its Ongoing Phase 1/2 VISTA-101 Clinical Trial And Corporate Activities; Received $500,000 Investment From An Existing Investor

Chat with this insight

Recent Analyst Ratings for
$KA

$KA
Press Releases

Fastest customizable press release news feed in the world

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1

$KA
SEC Filings

Kineta Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Kineta Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Kineta Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

$KA
Market Insights

Live Market Insights

Kineta shares are trading higher after the company announced that it entered into an exclusivity and right of first offer agreement with TuHURA Biosciences to grant the immune-oncology company exclusive rights to acquire its Anti-VISTA antibody.

TuHURA Biosciences And Kintara Therapeutics Announce Agreement For Potential Acquisition Of Kineta's Anti-VISTA Antibody

12 Health Care Stocks Moving In Thursday's After-Market Session

$KA
Leadership Updates

Live Leadership Updates

Kineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts to its Scientific Advisory Board

$KA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Kineta Inc. (Amendment)

$KA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Foote Marion R

SEC Form 4 filed by Director Iadonato Shawn

SEC Form 4 filed by Director Peters Richard

Kineta Provides Update On Its Ongoing Phase 1/2 VISTA-101 Clinical Trial And Corporate Activities; Received $500,000 Investment From An Existing Investor

Chat with this insight

Recent Analyst Ratings for $KA

$KA Press Releases

Fastest customizable press release news feed in the world

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1

$KA SEC Filings

Kineta Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Kineta Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Kineta Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

$KA Market Insights

Live Market Insights

Kineta shares are trading higher after the company announced that it entered into an exclusivity and right of first offer agreement with TuHURA Biosciences to grant the immune-oncology company exclusive rights to acquire its Anti-VISTA antibody.

TuHURA Biosciences And Kintara Therapeutics Announce Agreement For Potential Acquisition Of Kineta's Anti-VISTA Antibody

12 Health Care Stocks Moving In Thursday's After-Market Session

$KA Leadership Updates

Live Leadership Updates

Kineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts to its Scientific Advisory Board

$KA Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Kineta Inc. (Amendment)

$KA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Foote Marion R

SEC Form 4 filed by Director Iadonato Shawn

SEC Form 4 filed by Director Peters Richard

Recent Analyst Ratings for
$KA

$KA
Press Releases

$KA
SEC Filings

$KA
Market Insights

$KA
Leadership Updates

$KA
Large Ownership Changes

$KA
Insider Trading